Ozempic benefits and risks: separating facts from TikTok hype

What did @drcesarab2 actually say?

Honestly? Not much that's usable. The transcript here is almost entirely incoherent, apparently the result of a failed auto-transcription of what sounds like a Portuguese-language video. Phrases like "transfer your cells to my device" and "the original version of Enjidak" have nothing to do with semaglutide pharmacology. What we can work with is the caption, which correctly identifies Ozempic as a GLP-1 receptor agonist used for type 2 diabetes and weight loss.

The caption states that semaglutide is "used mainly for type 2 diabetes treatment and recently approved for weight loss." That framing is accurate as far as it goes. But because the spoken content of the video is unverifiable from this transcript, we're largely fact-checking the caption and the category context, not a coherent set of spoken claims.

Does the science back up the caption's framing?

Yes, the basic framing holds up. Semaglutide is FDA-approved under the brand name Ozempic for type 2 diabetes management and under Wegovy for chronic weight management. The evidence base is solid, though the caption's brevity leaves out important nuance.

The SUSTAIN trial series (Marso et al., 2016, New England Journal of Medicine) established semaglutide's cardiovascular benefit profile in type 2 diabetes patients at high cardiovascular risk, showing significant reductions in major adverse cardiovascular events. For weight loss, the STEP 1 trial (Wilding et al., 2021, NEJM) showed that adults with obesity treated with 2.4 mg weekly semaglutide lost an average of 14.9% of body weight versus 2.4% with placebo over 68 weeks. These are not trivial numbers. The caption's claim that semaglutide helps "control diabetes" and supports weight loss reflects the evidence accurately, if very broadly.

What did they get wrong, or right?

The caption gets the basic facts right: Ozempic is a brand name, semaglutide is the active compound, it is a GLP-1 receptor agonist, and it has both diabetes and weight loss applications. No argument there.

What's absent is the nuance that matters clinically. The caption promises a list of benefits and risks but the visible text cuts off at "Ajuda" ("helps"), so we can't evaluate what specific claims were made about benefits or harms. That's a real limitation. What we do know from the category context is that GLP-1 agonist content often understates side effect burden. Nausea, vomiting, and diarrhea affect a significant portion of users, particularly during dose escalation. The SELECT trial (Lincoff et al., 2023, NEJM) confirmed cardiovascular benefit in non-diabetic obese adults, but also documented gastrointestinal adverse events in roughly 44% of the semaglutide group. Any honest benefits-and-risks breakdown needs to include that prominently.

The spoken transcript is not evaluable as medical content. We're not going to pretend otherwise.

What should you actually know?

Semaglutide works by mimicking GLP-1, a hormone released after eating. It slows gastric emptying, reduces appetite signaling in the brain, and stimulates insulin secretion in a glucose-dependent manner. This is why it controls blood sugar without causing hypoglycemia on its own, and why it produces weight loss as a secondary effect in diabetic patients and a primary effect at higher doses in people with obesity.

A few things worth knowing that short-form video rarely covers adequately:

• Semaglutide is not interchangeable across its formulations. Oral semaglutide (Rybelsus), subcutaneous weekly semaglutide (Ozempic, Wegovy) have different bioavailability profiles and approved indications.
• Compounded semaglutide is not the same product as FDA-approved brand-name semaglutide. Regulatory status, purity standards, and clinical data do not transfer between them.
• Weight regain after stopping semaglutide is common. The STEP 4 withdrawal study (Rubino et al., 2021, JAMA) showed participants regained two-thirds of lost weight within a year of stopping.
• Pancreatitis risk, while low in absolute terms, is a documented concern. Patients with a history of pancreatitis or medullary thyroid carcinoma should not use GLP-1 agonists.
• GLP-1 agonists are prescription medications requiring medical supervision. They are not supplements and should not be self-administered without clinical oversight.